Aptar Pharma Partners with Lupin to Launch India’s First Connected Smart Device for Respiratory Disease, ADHERO

Aptar Pharma, a global leader in drug delivery systems, services and active packaging solutions, is pleased to announce that it has partnered with Lupin Limited to launch India’s first connected device for metered-dose inhalers (MDI) called ADHERO. This unique add-on smart device is designed to help patients with chronic respiratory diseases track their MDI usage and facilitate improved adherence to their prescribed therapy.

Inhalers are the preferred treatment option for managing the rising incidence of chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) in India. However, it is estimated that nearly 45 percent of patients do not adhere to their therapy, including the filling and refilling of prescriptions or maintaining the prescribed medication schedule. This inconsistent adherence adversely impacts clinical outcomes and the patient’s quality-of-life. This new device, ADHERO, is designed to improve patient adherence to therapy

ADHERO is a bluetooth-enabled, reusable smart device that attaches to the top of an MDI. With built-in sensors, the device tracks the patient’s daily medication usage and consumption patterns. Patients can access this information by connecting their ADHERO device to the “MyAdhero” app on their smartphones. The app is also equipped to send reminders, provide contextual health alerts based on factors like Air Quality Index at the patient’s current location and enable visual analytics. Patients can also grant their physician access to their information and medical tracking data through the dashboard portal as well as the app.

Aptar Pharma collaborated with Navia Life Care to develop the digital ecosystem for the MyAdhero App, which includes the Patient App, Care Provider App and the Doctor Portal.

Speaking about the launch, Rajeev Sibal, Lupin’s President India Region Formulations said, “Lupin lays great emphasis on three aspects of respiratory medicine, namely disease awareness, diagnosis and adherence. The launch of ADHERO will be a great help to patients using metered dose inhalers as well as for doctors to track adherence and compliance to therapy, thereby improving clinical outcomes and the quality-of-life of patients.”

Kanwal Tikoo, Aptar Pharma’s President of India & Southeast Asia commented, “We are pleased to have partnered with Lupin Limited on their ADHERO connected device program in India. With the steady rise in cases of asthma and COPD, this is an important step towards helping to improve adherence and health outcomes.”

Added Sai Shankar, Aptar Pharma’s Vice President, Global Digital Healthcare Systems, “Aptar Pharma has been building a portfolio of connected devices within the digital medicines ecosystem. We are focused on integrating services across device development and manufacturing, the digital platform experience and implementation with the healthcare stakeholders. We are excited about the first launch of a connected inhaler program for respiratory diseases in India with Lupin Limited.”

About Aptar Pharma

Aptar Pharma is part of AptarGroup Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active packaging solutions. Aptar uses insights, design, engineering and science to create dosing, dispensing and protective packaging technologies for the world’s leading brands, in turn making a meaningful difference in the lives, looks, health and homes of millions of people around the world. Aptar’s innovative solutions serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. The company is headquartered in Crystal Lake, Illinois and has 14,000 dedicated employees in 17 countries. For more information, visit www.aptar.com.
About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment. Please visit http://www.lupin.com for more information.
About Navia Life Care

Navia Life Care is a health technology company building digital platforms to improve patient care and experience. Founded in 2016, Navia is helping healthcare providers achieve higher clinical outcomes for their patients through innovative tools, which include a voice-enabled
digital Electronic Medical Record (EMR) system, an ML-based handwriting recognized EMR systems, and an AI-powered patient and queue management system. For more information, visit www.navialifecare.com.